Usefulness of multidisciplinary care to prevent worsening renal function in chronic kidney disease

Imamura, Yoshihiko; Takahashi, Yasunori; Hayashi, Takuma; Iwamoto, Masateru; Nakamura, Rie; Goto, Mikiko; Takeba, Kazuyo; Shinohara, Makoto; Kubo, S; Joki, Nobuhiko

doi:10.1007/s10157-018-1658-z

Cited by 16 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tables 1 and 2 detail the data extraction characteristics of controlled and uncontrolled studies included in the systematic review [ 15 – 61 ].…”

Section: Resultsmentioning

confidence: 99%

“…Structures were poorly reported in all studies, with only two giving some details of multidisciplinary team involvement [ 52 , 61 ], while, none on the pharmacist skill mix or time allocation. The only aspect of structures reported relating to training which was given in five studies.…”

Section: Resultsmentioning

confidence: 99%

“…Similar training was described for community pharmacists, [ 18 ] and hospital clinical pharmacists [ 16 ], to enable them to identify patients with renal insufficiency and perform dose adjustments. A four session course to all members of the multidisciplinary team prior to the study was described in one article [ 61 ].…”

Section: Resultsmentioning

confidence: 99%

“…However, one study demonstrated no difference in the mean serum creatinine or estimated glomerular filtration rate (eGFR) between the intervention and control groups [ 58 ]. A retrospective controlled study reported improvement in eGFR, uric acid, cholesterol and HbA1c in the intervention group compared to the control group after multidisciplinary care, however, pharmacists’ contribution to the care was not clearly reported [ 61 ].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review

et al. 2019

View full text Add to dashboard Cite

Background Clinical pharmacy services have potential to contribute significantly to the multidisciplinary team providing safe, effective and economic care for patients. Given recent practice developments (e.g. polypharmacy reviews and pharmacist prescribing) there is a need to provide a current synthesis of the evidence base for characteristics and outcomes of clinical pharmacy practice in chronic kidney disease patients. Aim of the review To critically appraise, synthesise and present the available evidence of the characteristics (structures and processes) and outcomes of clinical pharmacy practice as part of the multidisciplinary care of patients with chronic kidney disease. Method PubMed, International Pharmaceutical Abstracts (IPA), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medline and Scopus were searched for peer reviewed papers using improved search strategy. Included studies were quality assessed using Downs and Black tool for controlled studies and the mixed methods appraisal tool for all controlled and non-controlled studies. Data were extracted and synthesised using a narrative approach. Screening, quality assessment and data extraction were performed by two independent researchers. Ethics approval was not required. Results Forty-seven studies were identified from a variety of countries, with 31 based in a hospital setting. Controlled study designs were employed in 20, with only ten of these using randomisation. Resources available for service provision were poorly reported in all papers. Positive impact on clinical outcomes included significant improvement in parathyroid hormone, blood pressure, haemoglobin and creatinine clearance. Pharmacists identified 5302 drug related problems in 2933 patients and made 3160 recommendations with acceptance rates up to 95%. Impact on humanistic outcomes was shown through improvement in health related quality of life and patient satisfaction. Economic benefits arose from significant cost savings through pharmaceutical care provision. Conclusion While there is some evidence of positive impact on clinical, humanistic and economic outcomes, this evidence is generally of low quality and insufficient volume. While the existing evidence is in favour of pharmacists’ involvement in the multidisciplinary team providing care to patients with chronic kidney disease, more high-quality research is warranted. Electronic supplementary material The online version of this article (10.1007/s11096-019-00816-4) contains supplementary material, which is available to authorized users.

show abstract

“…Tables 1 and 2 detail the data extraction characteristics of controlled and uncontrolled studies included in the systematic review [ 15 – 61 ].…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…At this point, it is very important to educate patients and their caregivers about chronic kidney disease (CKD), which will hopefully postpone the need for dialysis or kidney transplantation. Kidney care programs play a role in kidney function [2][3][4][5], including Toprak's Kidney Care, which provides patient and caregiver trainings, suggests lifestyle changes, promotes regular nutrition and exercise, supplies adequate drugs in proper doses, improves morale and motivation, regulates fluid status, preserves residual kidney function, and offers nephroprotective alternative medicines.…”

Section: Introductionmentioning

confidence: 99%

Discontinuing Hemodialysis with Patient Care and a Successful 9-Year Follow-up in a Patient Presumed to have End-Stage Kidney Disease Scheduled to Lifelong Hemodialysis: A Case Report

Toprak

Bozyel

Alp

2021

Clinics and Practice

View full text Add to dashboard Cite

End-stage kidney disease patients who require hemodialysis for more than 3 months have a small chance of leaving dialysis unless they have a kidney transplant. Educating the patient about lifestyle changes can play a major role in improving kidney function. Therefore, we created a patient education program according to our nephrology experiences. Herein, we show an end-stage kidney disease patient who underwent hemodialysis for 6 months. Afterwards, dialysis was terminated with patient care, and the patient was then followed up for 9 years without dialysis. To date, there have been no reports regarding the termination of long-term dialysis with a kidney care program and the ensuing 9-year follow-up without renal replacement therapy.

show abstract

How to Prepare a Chronic Kidney Disease Patient for Dialysis

Correa-Rotter,

Ramírez-Sandoval

2023

Management of Chronic Kidney Disease

View full text Add to dashboard Cite

Usefulness of multidisciplinary care to prevent worsening renal function in chronic kidney disease

Cited by 16 publications

References 14 publications

Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review

Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review

Discontinuing Hemodialysis with Patient Care and a Successful 9-Year Follow-up in a Patient Presumed to have End-Stage Kidney Disease Scheduled to Lifelong Hemodialysis: A Case Report

How to Prepare a Chronic Kidney Disease Patient for Dialysis

Contact Info

Product

Resources

About